1-2 of 2
Maciej M. Mrugala
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Personalized tumor-specific amplified DNA junctions in peripheral blood of patients with glioblastoma

Mohamed F. Ali, Cecile Riviere-Cazaux, Sarah H. Johnson, Rebecca Salvatori, Alan R. Penheiter, James B. Smadbeck, Stephen J. Murphy, Faye R. Harris, Lex F. McCune, Lucas P. Carlstrom, Michael T. Barrett, Farhad Kosari, Leila A. Jones, Cristiane Ida, Mitesh J. Borad, Bernard R. Bendok, Alfredo Quiñones-Hinojosa, Alyx B. Porter, Maciej M. Mrugala, Kurt A. Jaeckle, Panos Z. Anastasiadis, Sani H. Kizilbash, John C. Cheville, David M. Routman, Terry C. Burns, George Vasmatzis
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-3233
Published: 28 February 2025
View article titled, Personalized tumor-specific amplified DNA junctions in peripheral blood of patients with glioblastoma
Open the PDF for Personalized tumor-specific amplified DNA junctions in peripheral blood of patients with glioblastoma in another window
Includes: Supplementary data
Journal Articles

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O'Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael J. Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1586–1594.
https://doi.org/10.1158/1078-0432.CCR-18-1140
Published: 01 April 2020
View article titled, Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Open the PDF for Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial in another window
Includes: Supplementary data